JP2018515491A5 - - Google Patents

Download PDF

Info

Publication number
JP2018515491A5
JP2018515491A5 JP2017557342A JP2017557342A JP2018515491A5 JP 2018515491 A5 JP2018515491 A5 JP 2018515491A5 JP 2017557342 A JP2017557342 A JP 2017557342A JP 2017557342 A JP2017557342 A JP 2017557342A JP 2018515491 A5 JP2018515491 A5 JP 2018515491A5
Authority
JP
Japan
Prior art keywords
cycloalkyl
alkylene
alkyl
phenyl
haloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017557342A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018515491A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/030882 external-priority patent/WO2016179343A1/en
Publication of JP2018515491A publication Critical patent/JP2018515491A/ja
Publication of JP2018515491A5 publication Critical patent/JP2018515491A5/ja
Pending legal-status Critical Current

Links

JP2017557342A 2015-05-05 2016-05-05 ＲＯＲγの作動薬及び疾患の療法として使用するジヒドロ−２Ｈ−ベンゾ［ｂ］［１，４］オキサジンスルホンアミド及び関連化合物 Pending JP2018515491A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562157224P 2015-05-05 2015-05-05
US62/157,224 2015-05-05
US201562210076P 2015-08-26 2015-08-26
US62/210,076 2015-08-26
PCT/US2016/030882 WO2016179343A1 (en) 2015-05-05 2016-05-05 DIHYDRO-2H-BENZO[b][1,4]OXAZINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE

Publications (2)

Publication Number Publication Date
JP2018515491A JP2018515491A (ja) 2018-06-14
JP2018515491A5 true JP2018515491A5 (enExample) 2019-05-30

Family

ID=57218639

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017557342A Pending JP2018515491A (ja) 2015-05-05 2016-05-05 ＲＯＲγの作動薬及び疾患の療法として使用するジヒドロ−２Ｈ−ベンゾ［ｂ］［１，４］オキサジンスルホンアミド及び関連化合物

Country Status (6)

Country Link
US (1) US10421751B2 (enExample)
EP (1) EP3292119A4 (enExample)
JP (1) JP2018515491A (enExample)
AU (1) AU2016257997A1 (enExample)
CA (1) CA2982847A1 (enExample)
WO (1) WO2016179343A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017507950A (ja) 2014-02-27 2017-03-23 リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ レチノイン酸受容体関連オーファン受容体ガンマのアゴニストを使用する養子細胞療法及び関連治療方法
JP6523337B2 (ja) 2014-05-05 2019-05-29 リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ ＲＯＲγのアゴニストとしての使用及び疾患治療のためのベンゼンスルホンアミド及び関連化合物
US9896441B2 (en) 2014-05-05 2018-02-20 Lycera Corporation Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease
AU2016257997A1 (en) 2015-05-05 2017-11-09 Lycera Corporation Dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORy and the treatment of disease
AU2016276947A1 (en) 2015-06-11 2017-12-14 Lycera Corporation Aryl dihydro-2h-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORy and the treatment of disease
CN112119065B (zh) * 2018-07-13 2024-01-23 四川科伦博泰生物医药股份有限公司 苯并二氮杂环类化合物、其制备方法及用途
CA3117113A1 (en) * 2019-01-23 2020-07-30 Abbisko Therapeutics Co., Ltd. 1,2,3,4-tetrahydroquinoxaline derivative, preparation method therefor and application thereof
TW202126618A (zh) * 2019-09-30 2021-07-16 大陸商上海輝启生物醫藥科技有限公司 磺基取代的聯芳基類化合物或其鹽及其製備方法和用途
WO2023016527A1 (zh) * 2021-08-13 2023-02-16 南京明德新药研发有限公司 一类苯并噁嗪螺环类化合物及其制备方法
WO2023016528A1 (zh) * 2021-08-13 2023-02-16 南京明德新药研发有限公司 一类苯并吗啉类化合物及其制备方法和用途
CN116283760B (zh) * 2022-12-30 2025-01-14 安徽英特美科技有限公司 一种6-溴喹啉的制备方法

Family Cites Families (156)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7210355A (enExample) 1971-08-03 1973-02-06
GB1447456A (en) 1973-06-20 1976-08-25 Teijin Ltd Process for preparing desmosterols
GB8607294D0 (en) 1985-04-17 1986-04-30 Ici America Inc Heterocyclic amide derivatives
DE3823318A1 (de) 1988-07-09 1990-02-22 Bayer Ag (hetero)aryloxynaphthaline mit ueber schwefel gebundenen substituenten
US5229115A (en) 1990-07-26 1993-07-20 Immunex Corporation Adoptive immunotherapy with interleukin-7
EP0567586B1 (en) 1991-01-16 1995-07-12 Schering Corporation Use of interleukin-10 in adoptive immunotherapy of cancer
TW263508B (enExample) 1991-02-12 1995-11-21 Pfizer
US5229109A (en) 1992-04-14 1993-07-20 Board Of Regents, The University Of Texas System Low toxicity interleukin-2 analogues for use in immunotherapy
JP3414433B2 (ja) 1993-03-01 2003-06-09 日本化薬株式会社 電子写真用トナー
DE19523446A1 (de) 1995-06-28 1997-01-02 Bayer Ag Benzotriazole
AU6490396A (en) 1995-07-14 1997-02-18 Smithkline Beecham Corporation Substituted-pent-4-ynoic acids
CN1198163A (zh) 1995-08-10 1998-11-04 拜尔公司 卤代苯并咪唑
EA002357B1 (ru) 1995-12-28 2002-04-25 Фудзисава Фармасьютикал Ко., Лтд. Производные бензимидазола
WO1997048697A1 (en) 1996-06-19 1997-12-24 Rhone-Poulenc Rorer Limited Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase
ATE265997T1 (de) 1996-06-21 2004-05-15 Allergan Inc Substituierte tetrahydronaphthalin- und dihydronaphthalin-derivate mit einer retinoiden und/oder retinoid antagonist-ähnlichen biologischen aktivität
DK0948495T3 (da) 1996-11-19 2004-06-01 Amgen Inc Aryl- og heteroarylsubstitueret, kondenseret pyrrol som antiinflammatoriske midler
US6392010B1 (en) 1996-12-19 2002-05-21 Aventis Pharmaceuticals Inc. Process for the solid phase synthesis of aldehyde, ketone, oxime, amine, hydroxamic acid and αβ-unsaturated carboxylic acid and aldehyde compounds
US6828344B1 (en) 1998-02-25 2004-12-07 Genetics Institute, Llc Inhibitors of phospholipase enzymes
JP4327915B2 (ja) 1998-03-30 2009-09-09 株式会社デ・ウエスタン・セラピテクス研究所 スルフォンアミド誘導体
SK3852001A3 (en) 1998-09-18 2003-03-04 Basf Ag 4-Aminopyrrolopyrimidines as kinase inhibitors
US6348032B1 (en) 1998-11-23 2002-02-19 Cell Pathways, Inc. Method of inhibiting neoplastic cells with benzimidazole derivatives
AU6762400A (en) 1999-08-12 2001-03-13 Cor Therapeutics, Inc. Inhibitors of factor xa
KR100720907B1 (ko) 1999-08-13 2007-05-25 바이오겐 아이덱 엠에이 인코포레이티드 세포 유착 억제제
WO2001021577A2 (en) 1999-09-20 2001-03-29 Takeda Chemical Industries, Ltd. Melanin concentrating hormone antagonist
AU2001285018A1 (en) 2000-08-17 2002-02-25 Agensys, Inc. Nucleic acids and corresponding proteins entitled 83p2h3 and catrf2e11 useful in treatment and detection of cancer
CZ20031515A3 (cs) 2000-11-09 2003-09-17 Neopharm, Inc. Komplexy SN-38 s lipidem a způsob jejich použití
TWI239942B (en) 2001-06-11 2005-09-21 Dainippon Pharmaceutical Co N-arylphenylacetamide derivative and pharmaceutical composition containing the same
PL372212A1 (en) 2001-08-03 2005-07-11 Schering Corporation Novel gamma secretase inhibitors
CA2457575C (en) 2001-08-17 2010-12-21 Sankyo Agro Company, Limited 3-phenoxy-4-pyridazinol derivatives and herbicidal composition containing the same
US7563882B2 (en) 2002-06-10 2009-07-21 University Of Rochester Polynucleotides encoding antibodies that bind to the C35 polypeptide
DE10229777A1 (de) 2002-07-03 2004-01-29 Bayer Ag Indolin-Phenylsulfonamid-Derivate
FR2845382A1 (fr) 2002-10-02 2004-04-09 Sanofi Synthelabo Derives d'indazolecarboxamides, leur preparation et leur utilisation en therapeutique
US6894061B2 (en) 2002-12-04 2005-05-17 Wyeth Substituted dihydrophenanthridinesulfonamides
UA80171C2 (en) 2002-12-19 2007-08-27 Pfizer Prod Inc Pyrrolopyrimidine derivatives
AU2003303231A1 (en) 2002-12-20 2004-07-14 Warner-Lambert Company Llc Benzoxazines and derivatives thereof as inhibitors of pi3ks
JP4601038B2 (ja) 2003-03-26 2010-12-22 第一三共株式会社 インドリルマレイミド類
US20080199486A1 (en) 2003-05-12 2008-08-21 Yair Argon Grp94-based compositions and methods of use thereof
EA010160B1 (ru) 2003-09-18 2008-06-30 Конформа Терапьютикс Корпорейшн Новые гетероциклические соединения - ингибиторы hsp90 и способы их получения
BRPI0414812A (pt) 2003-09-26 2006-11-14 Forbes Medi Tech Inc método de inibir a expressão de genes resistentes a múltiplos medicamentos e de inibir a produção de proteìnas resultantes da expressão de tais gene, melhorando assim a efetividade dos agentes quimioterápicos para tratar cánceres
WO2005033048A2 (en) 2003-09-29 2005-04-14 The Johns Hopkins University Wnt pathway antagonists
WO2005033288A2 (en) 2003-09-29 2005-04-14 The Johns Hopkins University Hedgehog pathway antagonists
SE0302760D0 (sv) 2003-10-20 2003-10-20 Biovitrum Ab New compounds
US7420059B2 (en) 2003-11-20 2008-09-02 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
JP4527730B2 (ja) 2003-12-09 2010-08-18 エフ．ホフマン−ラ ロシュ アーゲー ベンゾオキサジン誘導体及びその使用
ES2339670T3 (es) 2003-12-23 2010-05-24 Novartis Ag Inhibidores heterociclicos biciclicos de la quinasa p-38.
WO2005084208A2 (en) 2004-02-27 2005-09-15 New York University A novel class of sterol ligands and their uses in regulation of cholesterol and gene expression
WO2005120558A2 (en) 2004-05-25 2005-12-22 University Of Connecticut Health Center Methods for making compositions comprising heat shock proteins or alpha-2-macroglobulin for the treatment of cancer and infectious disease
EP2583678A3 (en) 2004-06-24 2013-11-13 Novartis Vaccines and Diagnostics, Inc. Small molecule immunopotentiators and assays for their detection
WO2006007486A2 (en) 2004-07-01 2006-01-19 New York University COMPOSITIONS AND METHODS FOR MODULATION OF RORϜt
FR2874011B1 (fr) 2004-08-03 2007-06-15 Sanofi Synthelabo Derives de sulfonamides, leur preparation et leur application en therapeutique
US20070010537A1 (en) 2004-08-20 2007-01-11 Kazumasa Hamamura Fused pyramidine derivative and use thereof
US7304073B2 (en) 2004-08-20 2007-12-04 Wyeth Method of treating myocardial ischemia-reperfusion injury using NF-kB inhibitors
US7652043B2 (en) 2004-09-29 2010-01-26 The Johns Hopkins University WNT pathway antagonists
US7998736B2 (en) 2004-10-08 2011-08-16 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy with enhanced T lymphocyte survival
JP2008521406A (ja) 2004-11-24 2008-06-26 フレッド ハッチンソン キャンサー リサーチ センター 養子免疫療法のためのｉｌ−２１の使用法および腫瘍抗原の同定法
AR051780A1 (es) 2004-11-29 2007-02-07 Japan Tobacco Inc Compuestos en anillo fusionados que contienen nitrogeno y utilizacion de los mismos
GB0514911D0 (en) 2005-07-20 2005-08-24 Univ Birmingham T cell memory assay
US8003624B2 (en) 2005-08-25 2011-08-23 Schering Corporation Functionally selective ALPHA2C adrenoreceptor agonists
AU2006283104A1 (en) 2005-08-25 2007-03-01 Pharmacopeia, Inc. Imidazole derivatives as functionally selective alpha2C adrenoreceptor agonists
ES2379098T3 (es) 2005-09-01 2012-04-20 Janssen Pharmaceutica Nv Derivados de benzopirano novedosos como abridores del canal de potasio
AU2006290803B2 (en) 2005-09-15 2009-11-26 F. Hoffmann-La Roche Ag Novel heterobicyclic derivatives useful as inhibitors of liver carnitine palmitoyl transferase
FR2896798A1 (fr) 2006-01-27 2007-08-03 Sanofi Aventis Sa Derives de sulfonamides, leur preparation et leur application en therapeutique
KR20080093123A (ko) 2006-02-13 2008-10-20 에프. 호프만-라 로슈 아게 당뇨병 치료용 헤테로바이사이클릭 설폰아마이드 유도체
CA2642211C (en) 2006-02-17 2012-01-24 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds for treating or preventing autoimmune diseases
KR20080098066A (ko) 2006-03-01 2008-11-06 얀센 파마슈티카 엔.브이. 림프구 제거제를 ｃｔｌ 및 사이토카인과 결합한 암 치료
EP2005177B1 (en) 2006-04-06 2013-07-10 Janssen R&D Ireland A homogeneous time resolved fluorescence based test method
US7998978B2 (en) 2006-05-01 2011-08-16 Pfizer Inc. Substituted 2-amino-fused heterocyclic compounds
US20080305169A1 (en) 2006-05-26 2008-12-11 Japan Tobacco Inc. Pharmaceutical Compositions Comprising Nitrogen-Containing Fused Ring Coumpounds
JP2009538910A (ja) 2006-06-01 2009-11-12 ワイス ５−ヒドロキシトリプタミン−６リガンドとしての１−スルホニルインダゾリルアミン誘導体および１−スルホニルインダゾリルアミド誘導体
EP2046741B1 (en) 2006-07-03 2012-10-31 Proximagen Ltd. Indoles as 5-ht6 modulators
EP2038301A4 (en) 2006-07-12 2010-01-20 Oncotx Inc COMPOSITIONS AND METHODS OF TARGETING CANCER-SPECIFIC TRANSCRIPTION COMPLEXES
TWI315304B (en) 2006-08-31 2009-10-01 Univ Taipei Medical Indoline-sulfonamides compounds
US8389739B1 (en) 2006-10-05 2013-03-05 Orphagen Pharmaceuticals Modulators of retinoid-related orphan receptor gamma
US20090275586A1 (en) 2006-10-06 2009-11-05 Kalypsys, Inc. Heterocyclic inhibitors of pde4
WO2008062740A1 (fr) 2006-11-20 2008-05-29 Japan Tobacco Inc. Composé azoté à anneaux fusionnés et son utilisation
US7799933B2 (en) 2006-12-21 2010-09-21 Hoffman-La Roche Inc. Sulfonamide derivatives
US20080186971A1 (en) 2007-02-02 2008-08-07 Tarari, Inc. Systems and methods for processing access control lists (acls) in network switches using regular expression matching logic
JP2010529031A (ja) 2007-05-29 2010-08-26 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Ｐｉ３キナーゼ阻害剤としてのナフチリジン誘導体
AU2008259792B2 (en) 2007-06-03 2013-08-22 Oncotx, Inc. Cancer related isoforms of components of transcription factor complexes as biomarkers and drug targets
US7776877B2 (en) 2007-06-22 2010-08-17 Chemocentryx, Inc. N-(2-(hetaryl)aryl) arylsulfonamides and N-(2-(hetaryl) hetaryl arylsulfonamides
EP2197876A1 (en) 2007-08-29 2010-06-23 Glaxosmithkline LLC Thiazole and oxazole kinase inhibitors
US7960376B2 (en) 2007-09-14 2011-06-14 Cara Therapeutics, Inc. Benzo-fused heterocycles
US8541185B2 (en) 2007-09-24 2013-09-24 Technion Research & Development Foundation Limited Method of predicting responsiveness to autologous adoptive cell transfer therapy
US20090131523A1 (en) 2007-10-15 2009-05-21 Enzymotec Ltd. Lipid compositions for the treatment and prevention of proliferative diseases and for the reduction of incidences of mutagenesis and carinogenesis
RU2364597C1 (ru) 2007-12-14 2009-08-20 Андрей Александрович Иващенко ГЕТЕРОЦИКЛИЧЕСКИЕ ИНГИБИТОРЫ Hh-СИГНАЛЬНОГО КАСКАДА, ЛЕКАРСТВЕННЫЕ КОМПОЗИЦИИ НА ИХ ОСНОВЕ И СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С АББЕРАНТНОЙ АКТИВНОСТЬЮ Hh СИГНАЛЬНОЙ СИСТЕМЫ
US7960377B2 (en) 2008-03-28 2011-06-14 Cara Therapeutics, Inc. Substituted pyridoxazines
WO2009147188A1 (en) 2008-06-05 2009-12-10 Glaxo Group Limited Benzpyrazol derivatives as inhibitors of pi3 kinases
ES2383246T3 (es) 2008-06-05 2012-06-19 Glaxo Group Limited 4-amino-indazoles
US8163743B2 (en) 2008-06-05 2012-04-24 GlaxoGroupLimited 4-carboxamide indazole derivatives useful as inhibitors of PI3-kinases
EP2288605B1 (en) 2008-06-09 2014-06-25 Sanofi Annelated pyrrolidin sulfonamides with oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals
BRPI0914978A2 (pt) 2008-06-09 2015-10-27 Sanofi Aventis sulfonamidas n-heterocíclicas reforçadas com grupo principal de oxadiazolona, processos para sua preparação e seu uso como farmacêuticos
US20110130384A1 (en) 2008-06-25 2011-06-02 Takeda Pharmaceutical Company Limited Amide compound
KR101963426B1 (ko) 2008-07-09 2019-03-28 닛산 가가쿠 가부시키가이샤 이속사졸린 치환 안식향산 아미드 화합물의 제조 방법
WO2010017827A1 (en) 2008-08-14 2010-02-18 European Molecular Biology Laboratory 6-substituted 1-sulfonyl-2, 3-dihydro-indole derivatives for the treatment of proliferative diseases
AU2009291595A1 (en) 2008-09-11 2010-03-18 University Of Florida Research Foundation, Inc. System and method for producing T cells
CA2739513A1 (en) 2008-10-02 2010-04-08 Taisho Pharmaceutical Co., Ltd. 7-piperidinoalkyl-3,4-dihydroquinolone derivative
EP2181710A1 (en) 2008-10-28 2010-05-05 Phenex Pharmaceuticals AG Ligands for modulation of orphan receptor-gamma (NR1F3) activity
WO2010057101A2 (en) 2008-11-17 2010-05-20 Schering Corporation Compounds useful as hiv blockers
US8716312B2 (en) 2008-11-19 2014-05-06 Merck Sharp & Dohme Corporation Inhibitors of diacylglycerol acyltransferase
CA2743669C (en) 2008-11-24 2018-10-16 Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt (Gmbh) High affinity t cell receptor and use thereof
CN102388054B (zh) 2008-12-19 2015-03-04 西特里斯药业公司 噻唑并吡啶沉默调节蛋白调节剂的化合物
TW201030007A (en) 2009-02-06 2010-08-16 Gruenenthal Gmbh Substituted spiro-amides as b1r modulators
JP5656880B2 (ja) 2009-03-09 2015-01-21 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ Ｐｉ３キナーゼの阻害剤としての４−オキサジアゾール−２−イル−インダゾール
TW201102391A (en) 2009-03-31 2011-01-16 Biogen Idec Inc Certain substituted pyrimidines, pharmaceutical compositions thereof, and methods for their use
WO2010123139A1 (ja) 2009-04-24 2010-10-28 持田製薬株式会社 スルファモイル基を有するアリールカルボキサミド誘導体
MY160454A (en) 2009-04-30 2017-03-15 Glaxo Group Ltd Oxazole substituted indazoles as pi3-kinase inhibitors
JP2013501057A (ja) 2009-08-03 2013-01-10 ユニバーシティー・オブ・マイアミ 制御性ｔ細胞のｉｎｖｉｖｏにおける増殖
US8119683B2 (en) 2009-08-10 2012-02-21 Taipei Medical University Aryl substituted sulfonamide compounds and their use as anticancer agents
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
CA2779303A1 (en) 2009-10-29 2011-05-19 Sirtris Pharmaceuticals, Inc. Bicyclic pyridines and analogs as sirtuin modulators
US20120245171A1 (en) 2009-12-03 2012-09-27 Glaxo Group Limited Benzpyrazole derivatives as inhibitors of pi3 kinases
WO2011067364A1 (en) 2009-12-03 2011-06-09 Glaxo Group Limited Novel compounds
WO2011067366A1 (en) 2009-12-03 2011-06-09 Glaxo Group Limited Indazole derivatives as pi 3 - kinase inhibitors
US8956860B2 (en) 2009-12-08 2015-02-17 Juan F. Vera Methods of cell culture for adoptive cell therapy
US20110142814A1 (en) 2009-12-16 2011-06-16 New York University Methods for Using Protein Kinase C-Theta Inhibitors in Adoptive Immunotherapy
AU2010347233B2 (en) 2010-03-01 2015-06-18 Oncternal Therapeutics, Inc. Compounds for treatment of cancer
IL300733B1 (en) 2010-03-05 2025-10-01 Univ Johns Hopkins Compositions and methods for antibodies and fusion proteins targeted for immune modulation
WO2011115892A1 (en) 2010-03-15 2011-09-22 Griffin Patrick R Modulators of the retinoic acid receptor-related orphan receptors
GB201004551D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
GB201013443D0 (en) 2010-08-11 2010-09-22 Cytovac As Compositions and methods for producing dendritic cells
DK2614058T3 (en) 2010-09-08 2015-09-28 Glaxosmithkline Ip Dev Ltd Polymorphs, and the salts of N- [5- [4- (5 - {[(2R, 6S) -2,6-dimethyl-4-morpholinyl] methyl} -1,3-oxazol-2-yl) -1H-indazole -6-yl] -2- (methyloxy) -3-pyridinyl] methanesulfonamide.
US9326987B2 (en) 2010-09-08 2016-05-03 Glaxo Group Limited Indazole derivatives for use in the treatment of influenza virus infection
WO2012037108A1 (en) 2010-09-13 2012-03-22 Glaxosmithkline Llc Aminoquinoline derivatives as antiviral agents
CA2816753A1 (en) * 2010-11-08 2012-05-18 Lycera Corporation N- sulfonylated tetrahydroquinolines and related bicyclic compounds inhibition of rory activity and the treatment of diseases
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
EP2487159A1 (en) 2011-02-11 2012-08-15 MSD Oss B.V. RorgammaT inhibitors
WO2012129394A2 (en) 2011-03-22 2012-09-27 Brigham And Women's Hospital, Inc. Methods and compositions for the treatment of cancer
KR101976882B1 (ko) 2011-03-23 2019-05-09 프레드 헛친슨 켄서 리서치 센터 세포 면역요법용 방법 및 조성물
WO2012127464A2 (en) 2011-03-23 2012-09-27 Gavish-Galilee Bio Applications Ltd Constitutively activated t cells for use in adoptive cell therapy
EP2511263A1 (en) 2011-04-14 2012-10-17 Phenex Pharmaceuticals AG Pyrrolo sulfonamide compounds for modulation of orphan nuclear receptor RAR-related orphan receptor-gamma (RORgamma, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune diseases
WO2012158784A2 (en) 2011-05-16 2012-11-22 Theodore Mark Kamenecka Modulators of the nuclear hormone receptor ror
EP2723347B1 (en) 2011-06-24 2019-09-04 GRI Bio, Inc. Prevention and treatment of inflammatory conditions
CN103957919B (zh) 2011-09-19 2018-10-16 瑞士苏黎世联邦理工学院 RORγ调节剂
GB201116641D0 (en) 2011-09-27 2011-11-09 Glaxo Group Ltd Novel compounds
WO2013074916A1 (en) 2011-11-18 2013-05-23 Board Of Regents, The University Of Texas System Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla
MX354717B (es) 2012-03-16 2018-03-16 Covagen Ag Moleculas de union novedosas con actividad antitumoral.
MX363350B (es) 2012-05-08 2019-03-20 Merck Sharp & Dohme COMPUESTOS DE SULFONA BICÍCLICA PARA LA INHIBICIÓN DE LA ACTIVIDAD RORgamma Y EL TRATAMIENTO DE ENFERMEDADES.
MX367341B (es) * 2012-05-08 2019-08-14 Merck Sharp & Dohme Tetrahidronaftiridina y compuestos biciclicos relacionados para la inhibicion de la actividad de rorgamma y el tratamiento de enfermedades.
WO2013167136A1 (en) 2012-05-08 2013-11-14 Herlev Hospital Improving adoptive cell therapy with interferon gamma
US9394315B2 (en) 2012-05-08 2016-07-19 Lycera Corporation Tetrahydro[1,8]naphthyridine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease
EP2856142A1 (en) 2012-05-25 2015-04-08 Health Diagnostic Laboratory, Inc. Rapid and high-throughput analysis of sterols/stanols or derivatives thereof
WO2014026328A1 (en) 2012-08-15 2014-02-20 Merck Sharp & Dohme Corp. 3-cyclohexenyl substituted indole and indazole compounds as rorgammat inhibitors and uses thereof
WO2014026327A1 (en) 2012-08-15 2014-02-20 Merck Sharp & Dohme Corp. 4-heteroaryl substituted benzoic acid compounds as rorgammat inhibitors and uses thereof
WO2014026329A1 (en) 2012-08-15 2014-02-20 Merck Sharp & Dohme Corp. N-alkylated indole and indazole compounds as rorgammat inhibitors and uses thereof
WO2014028669A1 (en) 2012-08-15 2014-02-20 Biogen Idec Ma Inc. Novel compounds for modulation of ror-gamma activity
WO2014026330A1 (en) 2012-08-15 2014-02-20 Merck Sharp & Dohme Corp. 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
PL3489261T3 (pl) 2012-08-24 2021-08-16 The Regents Of The University Of California Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu
EP2931267A1 (en) 2012-12-17 2015-10-21 INSERM - Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical compositions for the treatment of x-linked charcot-marie-tooth
US20150017120A1 (en) 2013-06-13 2015-01-15 Massachusetts Institute Of Technology Synergistic tumor treatment with extended-pk il-2 and adoptive cell therapy
US9663502B2 (en) 2013-12-20 2017-05-30 Lycera Corporation 2-Acylamidomethyl and sulfonylamidomethyl benzoxazine carbamates for inhibition of RORgamma activity and the treatment of disease
WO2015095795A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. TETRAHYDRONAPHTHYRIDINE, BENZOXAZINE, AZA-BENZOXAZINE, AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE
WO2015095792A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Carbamate benzoxaxine propionic acids and acid derivatives for modulation of rorgamma activity and the treatment of disease
JP2017507950A (ja) 2014-02-27 2017-03-23 リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ レチノイン酸受容体関連オーファン受容体ガンマのアゴニストを使用する養子細胞療法及び関連治療方法
JP6523337B2 (ja) 2014-05-05 2019-05-29 リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ ＲＯＲγのアゴニストとしての使用及び疾患治療のためのベンゼンスルホンアミド及び関連化合物
US9896441B2 (en) 2014-05-05 2018-02-20 Lycera Corporation Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease
AU2016257997A1 (en) 2015-05-05 2017-11-09 Lycera Corporation Dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORy and the treatment of disease

Similar Documents

Publication Publication Date Title
JP2018515491A5 (enExample)
EP1948649B1 (en) Fungicidal carboxamides
JP2016522266A5 (enExample)
JP2009536197A5 (enExample)
JP2016525075A5 (enExample)
JP2017514855A5 (enExample)
JP2017528415A5 (enExample)
JP2016525136A5 (enExample)
JP2016514718A5 (enExample)
JP2010535722A5 (enExample)
CA2667382A1 (en) Substituted dihydropyrazolones for treating cardiovascular and haematological diseases
JP2016514719A5 (enExample)
WO2008091580A2 (en) Fungicidal amides
JP2016535772A5 (enExample)
JP2014507464A5 (enExample)
JP2016525135A5 (enExample)
JP2016513660A5 (enExample)
JP2009532452A5 (enExample)
JP2018525375A5 (enExample)
JP2017517565A5 (enExample)
KR20160018811A (ko) 금속 효소 억제 화합물
JP2016532669A5 (enExample)
JP2020521766A5 (enExample)
ES2298853T3 (es) Aroilfuranos y aroiltiofenos apropiados para el tratamiento del cancer.
JP2018526416A5 (enExample)